HeartSciences Appoints New Scientific Advisory Board Member
Trade with 70% Backtested Accuracy
Analyst Views on HSCSW
No data
About the author
HeartSciences Shares Business Update and Announces Financial Results for First Quarter of Fiscal 2026
Company Overview: HeartSciences Inc. is an AI-powered medical technology company focused on enhancing ECGs/EKGs for earlier heart disease detection, recently achieving FDA Breakthrough Device Designation and launching the MyoVista Insights software platform.
MyoVista Insights Launch: The MyoVista Insights platform modernizes ECG management systems, allowing integration with existing devices and hospital workflows without additional capital expenditures, while also introducing CPT reimbursement codes for AI-ECG algorithms.
Financial Performance: For the first quarter of fiscal 2026, HeartSciences reported no significant revenue, with approximately $2.8 million in cash and $3.1 million in shareholders' equity, but has since raised additional funds to strengthen its balance sheet.
Future Plans: The company aims to submit its MyoVista wavECG device for FDA approval and expand its intellectual property portfolio, while positioning itself to achieve regulatory clearances and initial revenues in 2026.
HeartSciences Announces Conference Participation and Investor Webinar
Company Announcement: HeartSciences Inc., an AI-powered medical technology company, is hosting multiple virtual events in August 2025 to introduce its ECG/EKG technology and update investors, including an Investor Webinar on August 20 and a presentation at the Emerging Growth Conference 85 on the same day.
Product Focus: The company's MyoVista® wavECG™ aims to enhance cardiac screening by providing diagnostic information related to cardiac dysfunction, traditionally available only through imaging, while also delivering conventional ECG data.
HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
FDA Breakthrough Device Designation: HeartSciences Inc. has received FDA Breakthrough Device designation for its AI-powered ECG algorithm that detects Aortic Stenosis, a serious heart valve disease, potentially allowing for earlier diagnosis and treatment.
Clinical Advantages of the Algorithm: The algorithm integrates with hospital EHR systems, enabling real-time analysis of existing ECG data, expanding access to early diagnosis, especially in underserved areas, and improving patient outcomes through timely interventions.
Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences' Patent Portfolio and IP Value
Patent Grant Announcement: HeartSciences Inc. has received a foundational patent from the USPTO for estimating echocardiography parameters using ECG, enhancing its extensive intellectual property portfolio which now includes 10 US patents and 34 international patents.
Company Overview and Product Development: HeartSciences focuses on AI-powered ECG technology to improve cardiac screening, with its MyoVista® product designed to provide diagnostic information traditionally obtained through cardiac imaging, aiming for FDA clearance.
HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
Partnership Announcement: HeartSciences Inc. has signed its first commercial customer, Westcliffe Health Innovations in the UK, for its AI-powered ECG management platform, MyoVista Insights, aimed at improving heart disease detection.
Technology Overview: MyoVista Insights is a cloud-native system designed to enhance clinical decision-making and streamline ECG workflows, making it accessible for healthcare providers while reducing operational costs.
HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson
Investor Webinar Announcement: HeartSciences Inc. will host a live investor webinar on May 14, 2025, featuring CEO Andrew Simpson discussing the company's AI-powered ECG technology and current investment opportunities.
Company Overview: HeartSciences focuses on enhancing ECG diagnostic capabilities through AI, aiming to improve early detection of heart disease with its MyoVista® product candidate, which combines traditional ECG data with additional cardiac dysfunction insights.
HeartSciences Shares Business Update and Announces Financial Results for First Quarter of Fiscal 2026
Company Overview: HeartSciences Inc. is an AI-powered medical technology company focused on enhancing ECGs/EKGs for earlier heart disease detection, recently achieving FDA Breakthrough Device Designation and launching the MyoVista Insights software platform.
MyoVista Insights Launch: The MyoVista Insights platform modernizes ECG management systems, allowing integration with existing devices and hospital workflows without additional capital expenditures, while also introducing CPT reimbursement codes for AI-ECG algorithms.
Financial Performance: For the first quarter of fiscal 2026, HeartSciences reported no significant revenue, with approximately $2.8 million in cash and $3.1 million in shareholders' equity, but has since raised additional funds to strengthen its balance sheet.
Future Plans: The company aims to submit its MyoVista wavECG device for FDA approval and expand its intellectual property portfolio, while positioning itself to achieve regulatory clearances and initial revenues in 2026.
HeartSciences Announces Conference Participation and Investor Webinar
Company Announcement: HeartSciences Inc., an AI-powered medical technology company, is hosting multiple virtual events in August 2025 to introduce its ECG/EKG technology and update investors, including an Investor Webinar on August 20 and a presentation at the Emerging Growth Conference 85 on the same day.
Product Focus: The company's MyoVista® wavECG™ aims to enhance cardiac screening by providing diagnostic information related to cardiac dysfunction, traditionally available only through imaging, while also delivering conventional ECG data.
HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
FDA Breakthrough Device Designation: HeartSciences Inc. has received FDA Breakthrough Device designation for its AI-powered ECG algorithm that detects Aortic Stenosis, a serious heart valve disease, potentially allowing for earlier diagnosis and treatment.
Clinical Advantages of the Algorithm: The algorithm integrates with hospital EHR systems, enabling real-time analysis of existing ECG data, expanding access to early diagnosis, especially in underserved areas, and improving patient outcomes through timely interventions.
Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences' Patent Portfolio and IP Value
Patent Grant Announcement: HeartSciences Inc. has received a foundational patent from the USPTO for estimating echocardiography parameters using ECG, enhancing its extensive intellectual property portfolio which now includes 10 US patents and 34 international patents.
Company Overview and Product Development: HeartSciences focuses on AI-powered ECG technology to improve cardiac screening, with its MyoVista® product designed to provide diagnostic information traditionally obtained through cardiac imaging, aiming for FDA clearance.
HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
Partnership Announcement: HeartSciences Inc. has signed its first commercial customer, Westcliffe Health Innovations in the UK, for its AI-powered ECG management platform, MyoVista Insights, aimed at improving heart disease detection.
Technology Overview: MyoVista Insights is a cloud-native system designed to enhance clinical decision-making and streamline ECG workflows, making it accessible for healthcare providers while reducing operational costs.
HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson
Investor Webinar Announcement: HeartSciences Inc. will host a live investor webinar on May 14, 2025, featuring CEO Andrew Simpson discussing the company's AI-powered ECG technology and current investment opportunities.
Company Overview: HeartSciences focuses on enhancing ECG diagnostic capabilities through AI, aiming to improve early detection of heart disease with its MyoVista® product candidate, which combines traditional ECG data with additional cardiac dysfunction insights.
